TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7775320

Group type: EXPERIMENTAL
Intervention: Training in hot water (35 degrees C)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Training in cold water (20 degrees C)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Training in hot water and cold water
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Training in cold water
Number of subjects: 18
Study: 2181859

Group type: EXPERIMENTAL
Intervention: 2.2 g n-3 FAs/d (group 1)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 1.1 g n-3 FAs/d (group 2)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Olive oil (group 3, placebo control)
Number of subjects: 25
Study: 7000218

Group type: EXPERIMENTAL
Intervention: Brief hospital admission
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard admission
Number of subjects: 0
Study: 30073766

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg once daily for 16 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo once daily for 16 weeks
Number of subjects: 22
Study: 27808426

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 26399310

Group type: EXPERIMENTAL
Intervention: HFOs (High Frequency Oscillations)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Interictal spikes
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: HFOs
Number of subjects: 78
Study: 23942938

Group type: EXPERIMENTAL
Intervention: Patient-Specific Instrumentation (PSI)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional Instrumentation (Control)
Number of subjects: 40
Study: 21543671

Group type: EXPERIMENTAL
Intervention: Anatomical reconstruction of the lateral collateral ligament and popliteus tendon with tibialis posterior tendon allograft (Group A)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Modified biceps rerouting tenodesis (Group B)
Number of subjects: 46
Study: 19651410

Group type: EXPERIMENTAL
Intervention: Posterior cruciate ligament-retaining TKR design
Number of subjects: 29
Study: 18404608

Group type: EXPERIMENTAL
Intervention: High ACE activity group
Number of subjects: 16

Group type: COMPARATOR
Intervention: Low ACE activity group
Number of subjects: 16
Study: 16255753

Group type: EXPERIMENTAL
Intervention: Single-chamber ICDs (S-ICDs)
Number of subjects: 717

Group type: EXPERIMENTAL
Intervention: Dual-chamber ICDs (D-ICDs)
Number of subjects: 717
Study: 12143088

Group type: EXPERIMENTAL
Intervention: Nasal continuous positive airway pressure (nCPAP)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Mandibular advancement splint (MAS)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 24
Study: 10440558

Group type: EXPERIMENTAL
Intervention: Immunosuppressive therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: As-randomized (intention-to-treat) analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: As-treated analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Estimates based on a nonignorable selection model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rubin's causal model
Number of subjects: 0
Study: 8589023

Group type: EXPERIMENTAL
Intervention: Paclitaxel (175 mg/m2) and cisplatin (50 mg/m2)
Number of subjects: 20
Study: 2101251

Group type: EXPERIMENTAL
Intervention: Mouthrinse containing 0.03% triclosan and 0.25% copolymer
Number of subjects: 20
Study: 7230259

Group type: EXPERIMENTAL
Intervention: Self-control strategies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-control strategies with covert sensitization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-control manual and basic package
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Basic package with cue extinction procedures
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combination of self-control and cue extinction procedures
Number of subjects: 0
Study: 29737099

Group type: EXPERIMENTAL
Intervention: 200 mg voriconazole tablets
Number of subjects: 48
Study: 25712491

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Education pain intervention
Number of subjects: 294

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 294
Study: 24767206

Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 151

Group type: COMPARATOR
Intervention: Control
Number of subjects: 151
Study: 23071122

Group type: EXPERIMENTAL
Intervention: Ramipril (R; 10 mg daily)
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Telmisartan (T; 80 mg daily)
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Combination of Ramipril and Telmisartan (T+R)
Number of subjects: 422

Group type: COMPARATOR
Intervention: Clinic BP
Number of subjects: 422
Study: 20152972

Group type: EXPERIMENTAL
Intervention: Continuous support during labor
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (no continuous support)
Number of subjects: 100
Study: 18823194

Group type: EXPERIMENTAL
Intervention: Auditory pip
Number of subjects: 0

Group type: COMPARATOR
Intervention: Visual cues
Number of subjects: 0
Study: 16896736

Group type: EXPERIMENTAL
Intervention: VC (muscular contraction)
Number of subjects: 21

Group type: COMPARATOR
Intervention: VR (relaxed muscle)
Number of subjects: 21

Group type: COMPARATOR
Intervention: NV (no treatment)
Number of subjects: 21
Study: 14520020

Group type: EXPERIMENTAL
Intervention: Tomato juice (330 ml/day providing 37.0 mg/day lycopene)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carrot juice (330 ml/day providing 27.1 mg/day beta-carotene and 13.1 mg/day alpha-carotene)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Depletion period after juice intervention
Number of subjects: 0
Study: 10594270

Group type: EXPERIMENTAL
Intervention: Laparoscopic splenectomy (LS)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Open splenectomy (OS)
Number of subjects: 100
Study: 7567290

Group type: EXPERIMENTAL
Intervention: Cefixime (7.5 mg/kg orally twice daily for 14 days)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (50 to 70 mg/kg im once daily for 5 days)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Aztreonam (50 to 70 mg/kg im every 8 hours for 7 days)
Number of subjects: 124
Study: 2026339

Group type: EXPERIMENTAL
Intervention: Hypnotic relaxation period
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Acceleration suggestion period
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control period
Number of subjects: 6
Study: 6930476

Group type: EXPERIMENTAL
Intervention: Osseous recontouring
Number of subjects: 12

Group type: COMPARATOR
Intervention: Flap curettage
Number of subjects: 12
Study: 31594202

Group type: EXPERIMENTAL
Intervention: Heat treatment applied to trigger points
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 40
Study: 31585944

Group type: EXPERIMENTAL
Intervention: Penicillin V 800 mg four times daily for five days (total 16 g)
Number of subjects: 433

Group type: COMPARATOR
Intervention: Penicillin V 1000 mg three times daily for 10 days (total 30 g)
Number of subjects: 433
Study: 28111386

Group type: EXPERIMENTAL
Intervention: group‐AE (1.0 vol% 3‐acryloxypropyltrimethoxysilane+experimental resin)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: group‐BM (1.0 vol% 3‐acryloxypropyltrimethoxysilane+0.5 vol% bis‐(1,2‐triethoxysilyl)ethane+Multilink® Speed)
Number of subjects: 10
Study: 25829811

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg before PCI and for 5 days after PCI
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (10 mg daily after PCI)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Atorvastatin group
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 67
Study: 23498778

Group type: EXPERIMENTAL
Intervention: Epoprostenol AM
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Epoprostenol AS
Number of subjects: 40

Group type: COMPARATOR
Intervention: Epoprostenol GM
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: All formulations
Number of subjects: 40
Study: 21190035

Group type: EXPERIMENTAL
Intervention: 120% of VO₂max (120%(Wmax))
Number of subjects: 14

Group type: COMPARATOR
Intervention: 80% of the ventilatory threshold (80%(VT))
Number of subjects: 14
Study: 19689545

Group type: EXPERIMENTAL
Intervention: McMonnies Dry Eye Index
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Ocular Comfort Index (OCI)
Number of subjects: 70
Study: 16463053

Group type: EXPERIMENTAL
Intervention: Verapamil hydrochloride (calcium channel blocker), starting 3 days before SWL and continued for 4 weeks after the procedure
Number of subjects: 70

Group type: COMPARATOR
Intervention: Enforced fluid intake
Number of subjects: 70

Group type: COMPARATOR
Intervention: No specific medication (control group)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Verapamil hydrochloride
Number of subjects: 70

Group type: COMPARATOR
Intervention: High fluid intake
Number of subjects: 70
Study: 15001941

Group type: EXPERIMENTAL
Intervention: Desmopressin (20-40 microg intranasal) with conditioning alarm therapy
Number of subjects: 207

Group type: COMPARATOR
Intervention: Placebo nasal spray with conditioning alarm therapy
Number of subjects: 207
Study: 11318059

Group type: EXPERIMENTAL
Intervention: Self-generated drawing
Number of subjects: 0
Study: 9503347

Group type: EXPERIMENTAL
Intervention: Recruitment strategies including enlistment of a district advocate, meeting with teachers, using incentives, direct contact with parents, keeping rosters of consent forms, and tailoring strategies for subpopulations.
Number of subjects: 1698

Group type: EXPERIMENTAL
Intervention: Recruitment process at four levels: district, school, classroom, and individual.
Number of subjects: 1698

Group type: EXPERIMENTAL
Intervention: Examination of differences between participants and nonparticipants.
Number of subjects: 1698
Study: 7896541

Group type: EXPERIMENTAL
Intervention: Cisplatin 14 mg/m2 daily and 5-fluorouracil 700 mg/m2 daily for 5 days plus alpha-interferon 1 x 10(6) units/m2 daily for five days (phase I)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Cisplatin 17 mg/m2/day, 5-fluorouracil 700 mg/m2/day and alpha-interferon 3 x 10(6) units/m2/day (phase II)
Number of subjects: 23
Study: 3309298

Group type: EXPERIMENTAL
Intervention: Nalbuphine
Number of subjects: 141

Group type: COMPARATOR
Intervention: Diamorphine
Number of subjects: 141
Study: 31232898

Group type: EXPERIMENTAL
Intervention: Titrating CCRT
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Nontitrating CCRT
Number of subjects: 150

Group type: COMPARATOR
Intervention: No CCRT
Number of subjects: 150
Study: 28194093

Group type: EXPERIMENTAL
Intervention: 6 g whey protein + 2 g amylopectin-chromium complex (WPACr)
Number of subjects: 10

Group type: COMPARATOR
Intervention: 6 g whey protein (WP)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Comparison of WPACr and WP
Number of subjects: 10
Study: 25242569

Group type: EXPERIMENTAL
Intervention: 50-μg transdermal estradiol patch
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 24103853

Group type: EXPERIMENTAL
Intervention: Long-term psychodynamic psychotherapy (LTPP)
Number of subjects: 272

Group type: COMPARATOR
Intervention: Fluoxetine treatment
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Combination therapy (LTPP + Fluoxetine)
Number of subjects: 272
Study: 20729000

Group type: EXPERIMENTAL
Intervention: Arginine Vasopressin nasal spray (20 IU)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 41
Study: 18482348

Group type: EXPERIMENTAL
Intervention: Tougher and more adhesive food
Number of subjects: 9

Group type: COMPARATOR
Intervention: Other food
Number of subjects: 9
Study: 17175311

Group type: EXPERIMENTAL
Intervention: 7 x 10 g IVIG
Number of subjects: 50

Group type: COMPARATOR
Intervention: 7 x 10 g IV albumin
Number of subjects: 50
Study: 15041604

Group type: EXPERIMENTAL
Intervention: Patient-controlled epidural analgesia (PCEA; 0.125% ropivacaine plus sufentanil 1 microg/mL at a base rate of 12 mL/h and bolus application of 5 mL/15 min)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Conventional patient-controlled IV analgesia (PCIA; morphine 3 mg/15 min)
Number of subjects: 54
Study: 11461124

Group type: EXPERIMENTAL
Intervention: Sequential antibiotic therapy (switch therapy)
Number of subjects: 0
Study: 9426760

Group type: EXPERIMENTAL
Intervention: Tolterodine 1 mg twice daily
Number of subjects: 1120

Group type: EXPERIMENTAL
Intervention: Tolterodine 2 mg twice daily
Number of subjects: 1120

Group type: EXPERIMENTAL
Intervention: Oxybutynin 5 mg three times daily
Number of subjects: 1120

Group type: EXPERIMENTAL
Intervention: Tolterodine 1 mg and 2 mg
Number of subjects: 1120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1120
Study: 8356971

Group type: EXPERIMENTAL
Intervention: Eye prophylaxis
Number of subjects: 630
Study: 3688076

Group type: EXPERIMENTAL
Intervention: Grief support team's protocol of care
Number of subjects: 78

Group type: COMPARATOR
Intervention: Routine hospital care (Control)
Number of subjects: 78
Study: 29620994

Group type: EXPERIMENTAL
Intervention: 3 months of FOLFOX
Number of subjects: 3759

Group type: EXPERIMENTAL
Intervention: 6 months of FOLFOX
Number of subjects: 3759

Group type: EXPERIMENTAL
Intervention: 3 months of CAPOX
Number of subjects: 3759

Group type: EXPERIMENTAL
Intervention: 6 months of CAPOX
Number of subjects: 3759

Group type: COMPARATOR
Intervention: 6 months of treatment
Number of subjects: 3759
Study: 27283779

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan (lower doses: 100/50/0 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enalapril (lower doses: 5/2.5/0 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Any dose reduction (both treatments)
Number of subjects: 0
Study: 24974051

Group type: EXPERIMENTAL
Intervention: ODM-201 200 mg
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: ODM-201 400 mg
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: ODM-201 1400 mg
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: ODM-201 (all doses)
Number of subjects: 124
Study: 22091929

Group type: EXPERIMENTAL
Intervention: Choice of receiving test results either face-to-face or by letter
Number of subjects: 198

Group type: COMPARATOR
Intervention: Face-to-face consultation for DNA test result disclosure
Number of subjects: 198
Study: 20649630

Group type: EXPERIMENTAL
Intervention: Vildagliptin (50 mg twice daily)
Number of subjects: 3118

Group type: COMPARATOR
Intervention: Glimepiride (up to 6 mg/day)
Number of subjects: 3118

Group type: EXPERIMENTAL
Intervention: Vildagliptin
Number of subjects: 3118

Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 3118
Study: 18759658

Group type: EXPERIMENTAL
Intervention: CR60 compressor
Number of subjects: 10

Group type: COMPARATOR
Intervention: PortaNeb (PN) compressor
Number of subjects: 10
Study: 15948443

Group type: EXPERIMENTAL
Intervention: Alumina ceramic/alumina ceramic bearing
Number of subjects: 495

Group type: COMPARATOR
Intervention: Cobalt-chromium-on-polyethylene bearing
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: Alumina liner with thin metal backing
Number of subjects: 495
Study: 15228253

Group type: EXPERIMENTAL
Intervention: SPAS3 (sulfadoxine-pyrimethamine + artesunate for 3 days)
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: SPAS1 (sulfadoxine-pyrimethamine + artesunate for 1 day)
Number of subjects: 420

Group type: COMPARATOR
Intervention: SP (sulfadoxine-pyrimethamine alone)
Number of subjects: 420
Study: 11176977

Group type: EXPERIMENTAL
Intervention: Low-dose external beam irradiation at a dose of 14 Gy in 7 fractions of 2 Gy
Number of subjects: 83

Group type: COMPARATOR
Intervention: Sham radiation (observation group)
Number of subjects: 83
Study: 9646651

Group type: EXPERIMENTAL
Intervention: Sevoflurane and nitrous oxide
Number of subjects: 80

Group type: COMPARATOR
Intervention: Halothane and nitrous oxide
Number of subjects: 80
Study: 7875272

Group type: EXPERIMENTAL
Intervention: Inhalation of 125 micrograms carbachol
Number of subjects: 9

Group type: COMPARATOR
Intervention: Inflation of pneumatic trousers
Number of subjects: 9
Study: 2894181

Group type: EXPERIMENTAL
Intervention: Temazepam 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Temazepam 20 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 31833919

Group type: EXPERIMENTAL
Intervention: Evidence-based continuing care bundle
Number of subjects: 124
Study: 31905341

Group type: EXPERIMENTAL
Intervention: Aspirin (81 mg daily dose)
Number of subjects: 520

Group type: COMPARATOR
Intervention: Nonusers (no aspirin)
Number of subjects: 520
Study: 29432808

Group type: EXPERIMENTAL
Intervention: naloxegol 25 mg once daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study: 26911949

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg daily orally for at least 15 days
Number of subjects: 198

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 198
Study: 25695260

Group type: EXPERIMENTAL
Intervention: Clinic recruitment strategy
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Informatics recruitment strategy
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Community recruitment strategy
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Overall study retention
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Passive refusal rates
Number of subjects: 186
Study: 24094795

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (not applicable)
Number of subjects: 10
Study: 20730091

Group type: EXPERIMENTAL
Intervention: Meningococcal serogroup C conjugate vaccine (MenCC) administered at 14 months of age and catch-up immunization for ages 14 months to 18 years.
Number of subjects: 14925

Group type: EXPERIMENTAL
Intervention: Meningococcal serogroup C conjugate vaccine (MenCC) administered above 5 years of age.
Number of subjects: 14925

Group type: COMPARATOR
Intervention: Natural immunity (non-immunized adults).
Number of subjects: 14925

Group type: EXPERIMENTAL
Intervention: Catch-up immunization (MenCC) in children below 14 months of age.
Number of subjects: 14925

Group type: EXPERIMENTAL
Intervention: Catch-up immunization (MenCC) in adolescents.
Number of subjects: 14925
Study: 18787989

Group type: EXPERIMENTAL
Intervention: Coma Recovery Scale-Revised (CRS-R)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Glasgow Coma Scale (GCS)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Full Outline of UnResponsiveness scale (FOUR)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Wessex Head Injury Matrix (WHIM)
Number of subjects: 77
Study: 16600998

Group type: EXPERIMENTAL
Intervention: Men during 90 min bicycle exercise at 60% VO2peak
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Women during 90 min bicycle exercise at 60% VO2peak
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher proportion of type 1 muscle fibres in women
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher capillarization in women
Number of subjects: 0
Study: 12581006

Group type: EXPERIMENTAL
Intervention: Transurethral electrovaporization of the prostate (TUVP)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 235
Study: 10807465

Group type: EXPERIMENTAL
Intervention: Immunoadsorption (IA) and subsequent immunoglobulin G (IgG) substitution
Number of subjects: 18

Group type: COMPARATOR
Intervention: Conventional medical treatment (Control group)
Number of subjects: 18
Study: 8830979

Group type: EXPERIMENTAL
Intervention: Cabergoline under fasting conditions
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cabergoline under fed conditions
Number of subjects: 12

Group type: COMPARATOR
Intervention: Both fasting and fed conditions
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 12
Study: 1591948

Group type: EXPERIMENTAL
Intervention: Allopurinol (50 mg by mouth 4 times a day)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: DMSO (500 mg by mouth 4 times a day)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Control group (no specific treatment mentioned)
Number of subjects: 228
Study: 30866914

Group type: EXPERIMENTAL
Intervention: Verum electroacupuncture (EA) consisting of needling on 6 unilateral acupoints (LI4, LI15, TE14, SI9, SI11, and GB21) with electronic stimulation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham electroacupuncture (EA) using a non‐penetrating Park sham device and fake electronic stimulation on the same acupoints
Number of subjects: 60
Study: 27787890

Group type: EXPERIMENTAL
Intervention: GP2015
Number of subjects: 531

Group type: COMPARATOR
Intervention: ETN (Enbrel®)
Number of subjects: 531

Group type: EXPERIMENTAL
Intervention: Switching treatments
Number of subjects: 531
Study: 27173469

Group type: EXPERIMENTAL
Intervention: RVX-208 (100 mg b.i.d. for 29-33 days)
Number of subjects: 20
Study: 24815101

Group type: EXPERIMENTAL
Intervention: Combined oral contraceptives (COCs)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Progestin‐only pills (POPs)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Copper‐releasing intrauterine devices (IUDs)
Number of subjects: 162
Study: 22341427

Group type: EXPERIMENTAL
Intervention: Right ventricle-to-pulmonary artery shunt
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: Modified Blalock‐Taussig shunt
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: Pre-Norwood right ventricular fractional area change
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: Anatomy other than hypoplastic left heart syndrome
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: Lower socioeconomic status
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: Obstructed pulmonary venous return
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: Smaller ascending aorta
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: Genetic syndrome
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: Lower gestational age
Number of subjects: 549

Group type: COMPARATOR
Intervention: Shunt type
Number of subjects: 549
Study: 20655474

Group type: EXPERIMENTAL
Intervention: Quality of life assessment using WHOQoL-Bref
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Carer-related factors (emotional overinvolvement and burden of care)
Number of subjects: 81